Market Place
Sourcing Support
Apollomics Presents Vebreltinib Data At ESMO Congress 2024
16 Sep 2024 //
GLOBENEWSWIRE
Apollomics To Present At H.C. Wainwright Investment Conference
04 Sep 2024 //
GLOBENEWSWIRE
Apollomics Highlights Vebreltinib Progress And Reports H1 2024 Financial Results
14 Aug 2024 //
GLOBENEWSWIRE
Apollomics Reports Positive Data For Vebreltinib In Solid Tumors
13 Aug 2024 //
GLOBENEWSWIRE
Apollomics to Present at the Canaccord Genuity 44th Annual Growth Conference
08 Aug 2024 //
GLOBENEWSWIRE
Apollomics Gets 180-Day Extension To Regain Nasdaq Compliance
16 Jul 2024 //
GLOBENEWSWIRE
Apollomics Announces Updated Strategic Focus and Leadership Team Changes
03 Jul 2024 //
GLOBENEWSWIRE
Apollomics Announces Presentation at the 2024 BIO International Convention
29 May 2024 //
GLOBENEWSWIRE
Apollomics Private Placement, Board Addition
08 May 2024 //
GLOBENEWSWIRE
Apollomics` Vebreltinib Approved in China for MET+ Gliomas
25 Apr 2024 //
GLOBENEWSWIRE
Apollomics Presents Vebreltinib Data at AACR Annual Meeting
10 Apr 2024 //
GLOBENEWSWIRE
Predicine Announces Collaboration with Apollomics to Develop PredicineCARE
05 Apr 2024 //
GLOBENEWSWIRE
Apollomics Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency
19 Jan 2024 //
GLOBENEWSWIRE
Apollomics to Participate in a Fireside Chat at Oncology Conference
17 Jan 2024 //
GLOBENEWSWIRE
Apollomics to Present at the 2024 Biotech Showcase
02 Jan 2024 //
GLOBENEWSWIRE
Apollomics Announces Report of Activity of Vebreltinib in GBM
26 Oct 2023 //
GLOBENEWSWIRE
Apollomics Announces Presentations of Vebreltinib Data at ESMO 2023
16 Oct 2023 //
GLOBENEWSWIRE
Apollomics Reports First Half 2023 Financial Results
28 Sep 2023 //
GLOBENEWSWIRE
Apollomics Announces Closing of Business Combination and Listing on Nasdaq
30 Mar 2023 //
GLOBENEWSWIRE
Apollomics Inc. Receives FDA Orphan Drug Designation for Vebreltinib
15 Nov 2022 //
BIOSPACE
Apollomics is latest biotech to give SPACs a second chance
15 Sep 2022 //
FIERCEBIOTECH
Apollomics a Late-Stage Clinical Biopharmaceutical Company to be Listed
14 Sep 2022 //
GLOBENEWSWIRE
Apollomics expands leadership team with appointment of Dr Jane Wang as CSO
26 Jul 2022 //
BIOSPECTRUMASIA
Apollomics Expands Leadership Team with Appointment of Jane Wang, PhD as CSO
26 Jul 2022 //
GLOBENEWSWIRE
Apollomics doses first subject in Phase III AML therapy trial in China
23 Nov 2021 //
CLINICALTRIALSARENA
Apollomics Begins Dosing in Phase 3 Trial in GlycoMimetics’ Uproleselan for AML
23 Nov 2021 //
BUSINESSWIRE
Apollomics Doses First Patient in Phase 3 Clinical Trial with APL-106
22 Nov 2021 //
GLOBENEWSWIRE
Apollomics, Inc. Doses First Patient in a Phase I Clinical Trial of APL-102
10 Aug 2021 //
GLOBENEWSWIRE
Apollomics Doses First Patient in a Phase I Clinical Trial of APL-102
10 Aug 2021 //
PRESS RELEASE
Apollomics, Inc. Doses First Patient in a Phase I Clinical Trial of APL-102
10 Aug 2021 //
GLOBENEWSWIRE
Apollomics Doses First Patient in a Phase I Clinical Trial of APL-102
10 Aug 2021 //
PRESS RELEASE
Apollomics, Inc Doses First Patient in Ph1 Trial in China of GlycoMimetics’
04 Mar 2021 //
GLYCOMIMETICS
Apollomics, and Iterion Announce Exclusive Collaboration and License Agreement
10 Feb 2021 //
GLOBENEWSWIRE
Apollomics, and Edison Oncology Announce Licensing Agreement for Novel Protein
09 Feb 2021 //
GLOBENEWSWIRE
Apollomics, Inc. Closes $124 Million Series C Financing
06 Nov 2020 //
GLOBENEWSWIRE
Apollomics Receives China IND Approval for APL-106
28 Sep 2020 //
BIOSPACE
GlycoMimetics and Apollomics Announce Exclusive Collaboration
07 Jan 2020 //
BUSINESS WIRE
GlycoMimetics and Apollomics Announce Collaboration and License Agreement
06 Jan 2020 //
BIO SPACE
Cullinan Oncology Announces 1st Patients Dosed
19 Dec 2019 //
BUSINESS WIRE
